Study Details

Back to Search Results

A Swedish observational, prospective, multicentre study to evaluate patients ADHerence to a twice daily tacrolimus regimen and after conversion from twice daily to a once daily tacrolimus regimen in renal transplant recipients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.

N/A

Astellas Study ID

The unique identification code given by the study sponsor.

SE-ADV-NI-001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Kidney Transplants

Phase

N/A

Age

18 Years - N/A

Sex

Female & Male

Product

tacrolimus extended-release

Type

A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment.

Observational

Trial Dates

Jun 2012 - Sep 2015

Masking

Not Available

Enrollment number

59

A Swedish observational, prospective, multicentre study to evaluate patients ADHerence to a twice daily tacrolimus regimen and after conversion from twice daily to a once daily tacrolimus regimen in renal transplant recipients

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Swedish observational, prospective, multicentre study to evaluate patients ADHerence to a twice daily tacrolimus regimen and after conversion from twice daily to a once daily tacrolimus regimen in renal transplant recipients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo